Bone Biologics (BBLG) Net Income towards Common Stockholders (2010 - 2026)
Bone Biologics (BBLG) posted quarterly Net Income towards Common Stockholders of -$684643.0 for Q4 2025, up 55.01% year-over-year from -$441681.1 in Q4 2024, and down 2.69% quarter-over-quarter from -$666737.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Bone Biologics (BBLG) has reported Net Income towards Common Stockholders for 16 consecutive years, with -$684643.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Income towards Common Stockholders rose 55.01% year-over-year to -$684643.0; the TTM figure through Dec 2025 stood at -$3.1 million (up 57.8% YoY), while the FY2025 annual figure was -$3.1 million, up 57.56% from the prior year.
- Net Income towards Common Stockholders fell to -$684643.0 in Q4 2025 per BBLG's latest filing, from -$666737.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$176137.0 in Q4 2021 and bottomed at -$21.6 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged -$2.3 million across 5 years, with a median of -$848899.5 in 2024.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 12185.38% — and 2023, when it jumped 92.84%.
- Bone Biologics' Net Income towards Common Stockholders stood at -$176137.0 in 2021, then sank by 12185.38% to -$21.6 million in 2022, then surged by 92.84% to -$1.5 million in 2023, then grew by 1.82% to -$1.5 million in 2024, then soared by 55.01% to -$684643.0 in 2025.
- Business Quant data shows BBLG's Net Income towards Common Stockholders at -$684643.0 in Q4 2025, -$666737.0 in Q3 2025, and -$741421.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | -773,594.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -773,594.00 |
| Dec 31, 2025 | -684,643.00 |
| Sep 30, 2025 | -666,737.00 |
| Jun 30, 2025 | -741,421.00 |
| Mar 31, 2025 | -1.02 Mn |
| Dec 31, 2024 | -1.52 Mn |
| Sep 30, 2024 | -4.15 Mn |
| Jun 30, 2024 | -794,518.00 |
| Mar 31, 2024 | -903,281.00 |
| Dec 31, 2023 | -1.55 Mn |
| Sep 30, 2023 | -1.92 Mn |
| Jun 30, 2023 | -3.04 Mn |
| Mar 31, 2023 | -3.15 Mn |
| Dec 31, 2022 | -1.29 Mn |
| Sep 30, 2022 | -1.22 Mn |
| Jun 30, 2022 | -437,827.00 |
| Mar 31, 2022 | -689,499.00 |
| Dec 31, 2021 | -176,137.00 |
| Sep 30, 2021 | -509,303.00 |
| Jun 30, 2021 | -491,898.00 |